The Kirby Institute has released a newsletter with data compiled from the Pharmaceutical Benefits Scheme on the initiation of hepatitis C treatment since new direct acting antivirals medications became publicly listed. A total of 1,811 individuals initiated chronic hepatitis C therapy. The data is broken down by each state and territory, as well as regimen and course duration.
The new medications have a high cure rate for chronic hepatitis C and fewer side effects than previous treatments.
We are likely to see a dramatic increase in numbers in the second and possibly third month, as reimbursements for scripts move through the system and are recorded as data.
Download the Kirby Report